Comparison of two groups of anti cancer drugs for treatment of Retinoblastoma, a tumour of eye

Vincristine and Topotecan versus Carboplatin, Etoposide and Vincristine based chemotherapy for ocular salvage in Gr D Intraocular Retinoblastoma: a randomised, open label trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037452

Enrollment

Registered

2021-10-21

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C692- Malignant neoplasm of retina

Interventions

Intervention1: Vincristine,Topotecan: Chemotherapy agents will be given for 6 cycles. The duration of each cycle is 5 days and it will be repeated every 21 days. Total duration of study is 2 years Con

Eligibility

Inclusion criteria

Inclusion criteria: 1.All cases of newly diagnosed Unilateral Group D Intraocular Retinoblastoma 2. All cases of newly diagnosed bilateral Intraocular Retinoblastoma with at least one eye with Group D Intraocular Retinoblastoma 3. Age less than 12 years

Exclusion criteria

Exclusion criteria: 1.Received any prior anti-neoplastic or local ophthalmic therapy 2. Group E Intraocular retinoblastoma 3. Relapsed cases

Design outcomes

Primary

Measure	Time frame
To compare treatment failure rate between Vincristine and Topotecan (VT) combination and Carboplatin, Etoposide and Vincristine (CEV) combination chemotherapy after 6 cycles of chemotherapy in children aged less than 12 years with Group D Intraocular retinoblastomaTimepoint: To compare treatment failure rate between Vincristine and Topotecan (VT) combination and Carboplatin, Etoposide and Vincristine (CEV) combination chemotherapy after 6 cycles of chemotherapy in children aged less than 12 years with Group D Intraocular retinoblastoma	—

Measure

Time frame

To compare treatment failure rate between Vincristine and Topotecan (VT) combination and Carboplatin, Etoposide and Vincristine (CEV) combination chemotherapy after 6 cycles of chemotherapy in children aged less than 12 years with Group D Intraocular retinoblastomaTimepoint: To compare treatment failure rate between Vincristine and Topotecan (VT) combination and Carboplatin, Etoposide and Vincristine (CEV) combination chemotherapy after 6 cycles of chemotherapy in children aged less than 12 years with Group D Intraocular retinoblastoma

—

Secondary

Measure	Time frame
1. To compare vision salvage in both the groups 2. To compare the toxicity profile between both the groupsTimepoint: 6 months	—

Countries

India

Contacts

Public ContactProf Rachna Seth

AIIMS New Delhi

prashant15prabhakar@gmail.com8800719116

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026